Back to People

Kevin Chu

Principal

About

Kevin Chu joined F-Prime Capital in 2014 and is currently a Principal on the healthcare investment team based in San Francisco. Prior to F-Prime, Kevin was an Associate Consultant with IMS Consulting Group in New York, where he advised biopharmaceutical clients on development and commercial strategy.

At F-Prime, Kevin focuses primarily on investments in therapeutics, medical devices, and life science tools companies. He was a member of the founding team at Shinobi Therapeutics, led the fund’s investments in Cadence Neuroscience and Amber Therapeutics, and was involved with several legacy fund investments including Innovent Biologics (1801.HK), Semma Therapeutics (acquired by Vertex), Modis Therapeutics (acquired by Zogenix), Farapulse (acquired by Boston Scientific), Cytek Biosciences (NASDAQ: CTKB), and Sipai Health Technology (0314.HK). He also works closely with the Eight Roads Ventures China team to manage F-Prime’s healthcare investment efforts in China.

Kevin holds a B.S.E. from the University of Pennsylvania where he studied Bioengineering and Engineering Entrepreneurship.

  • Adagene (Nasdaq: ADAG) is an antibody discovery and engineering company with proprietary Smart Antibody Technology, which increases success rates, substantially accelerates time to market, and reduces the costs associated with developing a therapeutic antibody. Learn more at www.adagene.com.

    • Category

      • Therapeutics

    • Status

      • Public

    • Location

      Suzhou, China

    • Year Invested

      2011

    • Team

      Chong Xu, Ph.D.

  • Amber Therapeutics is developing Amber-UI, a breakthrough adaptive neuromodulation therapy to treat women suffering with mixed urinary incontinence with the hope of transforming the clinical outcome and quality of life of a large untreated population. Amber-UI runs on the Company’s fully implantable Picostim system that targets the pudendal nerve to both stimulate and sense physiological responses. The therapy is configurable to the individual’s need and can respond dynamically to different events, adapting as needed between modes of operation. Amber’s technology platform is highly versatile and can be used to explore other novel therapy applications in both the pelvis and the broader nervous system, demonstrated by the work being carried out by the Company’s academic partnerships. Learn more at www.amber-tx.com.

  • The company specializes in personalized full-cycle cancer treatments and management, from prevention and early test of symptoms to the adoption of advanced cancer treatment methods. Learn more at www.arion.care.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Beijing, China

    • Year Invested

      2019

    • Team

      Kevin Chu

  • Avivomed, is a medical device company developing innovative neuromodulation technology to treat large disease populations.  Learn more at www.avivomed.com.

     

  • b-ONE Ortho Corp. is an emerging orthopedic technology company dedicated to the development of innovative orthopedic healthcare solutions that restore patient mobility and improve surgical outcomes. Every day we are committed to becoming the most credible choice for orthopedic products worldwide.

    Learn more at b1.co.

  • Cadence Neuroscience is a medical device company developing new therapies for the treatment of epilepsy and other neurological disorders. The company’s core technology was developed at Mayo Clinic and is under clinical evaluation. Founded in 2017 and headquartered in Redmond, Washington, Cadence is led by seasoned executives with extensive backgrounds in neural implant product development and clinical studies. Learn more: https://www.cadenceneuro.com/

  • Curegenix is a Chinese leader in discovery and development of novel drugs in stem cell related diseases. Learn more at www.curegenix.com.

    • Category

      • Therapeutics

    • Status

      • Private

    • Location

      China

    • Year Invested

      2016

    • Team

      Kevin Chu

  • Cytek Biosciences Inc.  (NASDAQ: CTBK) is a leading flow cytometry solution provider that provides compact, affordable instruments with high multiplexing capabilities. Learn more at www.cytekbio.com.

    • Category

      • MedTech

    • Status

      • Public

    • Location

      China

    • Year Invested

      2015

    • Team

      Kevin Chu

  • Through the synergies of cross-disciplinary collaboration and technological innovation, EurekaBio has consistently pushed the boundaries of therapy. EurekaBio has brought forth advanced cellular drug production solutions and the EuLV™ lentiviral vector platform. These breakthroughs, including high-titer stable lentiviral vector packaging and producer cell lines, are poised to play a pivotal role in the global commercialization of CGT drugs. Our ultimate aim is to bring tangible benefits to patients worldwide by ushering in a new era of advanced and accessible therapies. Learn more: https://www.eurekabio.com/

  • Farapulse is a medical device company developing a novel approach to treating a range of arrhythmias using pulsed electric field. Farapulse was acquired by Boston Scientific in 2021.

  • Gu Sheng Tang (“GST”) is a Guangzhou, China-based healthcare services provider that operates a chain of private clinics specializing in traditional Chinese medicine. Learn more at www.gstzy.cn.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Guangzhou, China

    • Year Invested

      2015

    • Team

      Kevin Chu

  • Huan Qui Li Kang Technology Co., Ltd. (“HQ”) is an early stage hemostatic product manufacturer in China.

  • Hua Medicine (2552.KHK) is a leading clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders. Learn more at www.huamedicine.com.

  • KnowYourself is a digital health company that is focused on promoting mental wellness in China.

    Learn more at knowyourself.cc.

  • MDDF is a medical device company focused on the manufacturing, development, and commercialization of high quality, affordably priced cardiovascular and general surgery medical devices for the Chinese market.

     

    • Category

      • MedTech

    • Status

      • Private

    • Location

      Beijing, China

    • Year Invested

      2011

    • Team

      Kevin Chu

  • Medbanks (0314:HK) is building a data service platform for oncologists and cancer care centers in China. Learn more at www.medbanks.cn.

  • Modis Therapeutics, Inc. was formed in 2016 through a collaboration with academic experts in mitochondrial biology. The company’s lead program (MT1621) is in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease. Modis Therapeutics is headquartered in Oakland CA, with offices in New York City. Modis was acquired by Zogenix.

    • Category

      • Therapeutics

    • Status

      • Acquired

    • Location

      Oakland, CA

    • Year Invested

      2018

    • Team

      Kevin Chu

  • OriGynMED is a developer of medical devices designed for women’s health. The company is mainly engaged in developing various gynecology medical devices such as hysterectomy cold knife and functional hysteroscope, enabling client to improve treatment effect. Learn more at www.origynmed.com.

    • Category

      • MedTech

    • Status

      • Private

    • Location

      Hangzhou, China

    • Year Invested

      2015

    • Team

      Kevin Chu

  • RareCyte offers Precision Biology™ solutions focused on multiplexed analysis of cells and tissue with applications in both research and clinical diagnostics. The Company has deep experience in developing advanced precision life science systems used in cutting-edge labs worldwide. RareCyte customers perform innovative research, bring new therapeutics to market, and perform a wide range of single cell applications in oncology and disease research. Learn more at www.rarecyte.com.

  • REDPINE is a medical technology company that provides complete solutions for medical business. It focuses on the research and development and production of single-use Class III medical devices, initially endoscopes for urology and gynecology. Learn more at en.gzredpine.com.

  • Shinobi Therapeutics is a biotechnology company developing a new class of off-the-shelf immune evasive iPSC-derived cell therapies. Based on the research of scientific co-founders Shin Kaneko, M.D., Ph.D., at Kyoto University and Tobias Deuse, M.D., at University of California, San Francisco, Shinobi has created a new allogeneic CD8αβ iPS-T cell platform that demonstrates comprehensive immune evasion from all arms of the immune system. For more information, please visit www.shinobitx.com.

  • TreeENT is a Hangzhou, China-based operator of private, premium-positioned ambulatory surgery centers (ASCs) focused on high volume, high unmet need, and self-pay surgery markets.

    Learn more at treeent.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Hangzhou, China

    • Year Invested

      2019

    • Team

      Carl Byers, Kevin Chu

  • Zenflow is a medical device company developing the Spring Implant for patients with benign prostate hyperplasia (BPH). Learn more at www.zenflow.com.